ims health 2011 strengths and limitations of market intelligence data for pharmaceutical policy...
TRANSCRIPT
![Page 1: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/1.jpg)
IMS Health 2011
Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC
ICIUM 2011 - Third International Conference for Improving Use of Medicines
Antalya, November 2011
![Page 2: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/2.jpg)
Agenda
• Introduction to:
– Volume data– Medical Data
• Sampling and projection• Data quality process• Summary
What do we collect, why do we collect it in that way & where we collect it
![Page 3: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/3.jpg)
3
Volume data
![Page 4: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/4.jpg)
4
Volume data: Collected from different parts of the supply chain, depending on the country
![Page 5: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/5.jpg)
5
Consumers
Retail drugstores type A & B
Health centers & private clinics
Non drugstore outlets
72%
1%
Wholesalers6%
Manufacturers
Results are based on information provided by 27 manufacturers that represent 30% of the market share.
Updated 2010
Status 2009
Agents/distributors Own distributor
5%
Special hospitals
General hospitals
18%
3% 1%
71%
70%
2%
Market covered by TLPI Market covered by TLHI
ThailandChannels of distribution
![Page 6: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/6.jpg)
6
Ecuador – multi-source sampling
Data sources: MF data (unprojected) Distributor data (unprojectable) Wholesaler data (projectable) Chain pharmacies (unprojectable) Independent pharmacies (projectable)
![Page 7: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/7.jpg)
Data points Information typically captured (volume data)
Wholesaler Pharmacy Hospitals
Segment (not released)
(not released)
(aggregated)
Location - (aggregated)
(aggregated)
Pack details
Quantity
Price ? ? ?
Derived characteristics(EPhMRA ATC, Manufacturer, Corporation, Molecule, Salt,
Launch, Brand/Unbranded, Volume (Units, SU or Kg)
![Page 8: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/8.jpg)
9
Medical data
![Page 9: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/9.jpg)
10
Diagnosis
• ICD10 codes• Doctor wording• Co-diagnoses• Treated/untreated
Patient demographics
• Age• Sex• Smoker/non-smoker• Insurance
Doctor demographics
• Age, sex• Speciality• Year qualified• University• Region
Therapy
• Product prescribed• Desired effect• Co-prescription• ATC, NDF• Dosage data
Information captured in medical data
No in-patient
![Page 10: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/10.jpg)
Country Doctors in period (Q, T, S)
Argentina 470
Brazil 1,315
Colombia 385
Indonesia 450
Lebanon 248
Mexico 1,050
Pakistan 540
Peru 565
Philippines 350
Poland 565
South Africa 385
Thailand 440
Turkey 705
Venezuela 500
Medical Data Availability – Low and Middle Income
+ 29 HI
![Page 11: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/11.jpg)
12
Sampling and Projection
![Page 12: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/12.jpg)
13
The right balance determines the relevance of our measurements
Sampling and projectionKey elements of sampling concepts
![Page 13: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/13.jpg)
14
Sampling and projectionSample design stratification
Weighting variables
+ Geospatial
![Page 14: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/14.jpg)
15
Data quality
![Page 15: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/15.jpg)
16
Random Error:Unviewed ≠ sample
• Sample size• Stratification• Selection
Systematic Error=data collection
• Non-response• Incomplete reporting
• Reporting time• Reporting quality
Data quality – sampling error components
![Page 16: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/16.jpg)
17
Data quality: Sample design
Key stats factors Description
Data sources 417 wholesalers/chains; 130 pharmacies
Sample type Multi-source panel
Sampling ratio 99%
Data availability Monthly
Shortcomings Some local MF only captured through panelNon-retail channel incomplete
Brazil
![Page 17: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/17.jpg)
18
Data quality: Minimising systematic error
![Page 18: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/18.jpg)
19
• Since 1964, in collaboration with industry associations (EPhMRA, BPIRG), we conduct annual comparisons with our customers, contrasting IMS data estimates with actual industry sales.
• These ‘validation studies’ are carried out in more than 60 markets with ~ 2,200 pharmaceutical companies, covering more than 70,000 product forms.
• The results are published once a year in the IMS Annual Report on Quality Assurance – ACTS.
• All validation studies follow the same uniform procedure and reporting is standardized in order to allow cross-country comparisons and easy reading.
IMS Annual Validation Studies (for sales data)
![Page 19: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/19.jpg)
20
Bias (only for sales data)
Average over/underestimation of the real market performance:
Total IMS units of all validated product forms
Total real units of all validated product forms
Pack IMS Units
A 1,000
B 1,200
C 4,000
Example:
D 6,500
E 7,200
Total 19,900
Real Units
900
1,500
3,800
7,000
7,400
20,600
R-Value
1.111
0.800
1.053
0.929
0.973
0.966
Bias= -3.4%
![Page 20: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/20.jpg)
21
Precision Index (only for sales data)Example of Precision
Index Precision
Total1.4751.3751.2751.1751.0750.9750.8750.7750.6750.5750.475from
1.5251.4751.3751.2751.1751.0750.9750.8750.7750.6750.575
to
2,280 5 25 45 100 410 770 590 230 55 35 15
No. ofR-Values
R-Value Class
0
100
200
300
400
500
600
700
800R-Value Distribution
Σ = 2,070
90.8% 100 *2,2802,070
Index Precision
R-Valuesinside ±22.5%deviation rangeR-Values in total
2,070
2,280
![Page 21: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/21.jpg)
22
Share of total volume used in
validation comparison (2009)
Latvia = 27%Malaysia = 29%Mexico = 36%Turkey = 66%
Venezuela = 72%
![Page 22: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/22.jpg)
23
Limitations of data utilization
• Prices– Collected only at one point in supply chain– Generally list prices– Discounting not always known or able to be taken into account
• Coverage– Not all channels, and samples of channels– Often combines public and private in same audit
• Accuracy varies by product size for sample-based data– Almost all audits are sample based
• Inpatient prescribing not available– Cross country comparisons using medical data needs to bear in mind
specialty mix
![Page 23: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/23.jpg)
24
• Reimbursement policy assessment and impact• Generic market evolution
• Generics policies and impact
• Pricing policy impact on volume
• Potential savings (using country own price data)
• Medicines shortages
• Quality of care initiatives assessment and impact• Unwarranted variations in volumes
• Pharmaceutical “gaps”
• Usage by indication
• Exposure studies
• Adherence to guidelines• WHO/National Essential Drug List• Therapy area formularies e.g. antibiotics
![Page 24: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/24.jpg)
25
THANK YOU!
![Page 25: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/25.jpg)
26
IMS Institute for Healthcare InformaticsGlobal Health Research Program
Murray Aitken, Executive Director, IMS Institute for Healthcare Informatics
![Page 26: IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference](https://reader035.vdocuments.us/reader035/viewer/2022062716/56649e0b5503460f94af2c25/html5/thumbnails/26.jpg)
27
IMS Institute for Healthcare InformaticsGlobal Health Research Program
• Objective• Elements of the program
• Access to IMS Health data and support• Training and education• Coordination and alignment of activities• Terms and conditions of support
• Program operation• External Advisory Council• Research agenda priorities• Research proposal criteria